Super-globuling for in vivo extended lifetimes

Details Super-globuling for in vivo extended lifetimes Super-globuling for in vivo extended lifetimes

1994-05-03

1997-03-18

Feisee, Lila

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

530402, 530328, 530327, 530326, 514 1, 4241931, A61K 3900, A61K 3800

Patent

active

056120346

ABSTRACT:
First and second compounds are provided, where the first compound is administered to a mammalian host into blood for covalent bonding to blood components, where the components have an extended lifetime in the blood stream. The first compound comprises an active functionality and an agent of interest or a first binding entity. A second compound may be subsequently administered to the patient, which comprises a second binding entity, complementary to the first binding entity and an agent of interest. By virtue of binding to long-lived blood components, the half-life of the agent of interest is greatly extended in vivo.

REFERENCES:
patent: 4971792 (1990-11-01), Steplewski et al.
Tao et al. The Journal o f Immunology vol. 143 No. 8 Oct. 15, 1989 p. 2595.
Gillies et al. Human Antibodies and Hybridomas. 1990 vol. 1 No. 1 p. 47.
Burgess et al. Journal of Cell Biology Vol. IIII Nov. 1990 2129.
Ghose et al. J.N. Cancer Inst 61(3) 1978 p. 657.
Coller et al., "Thromboerythrocytes," J. Clin. Invest. (1992) 89:546-555.

Affiliated with

Also associated with

Rating

Super-globuling for in vivo extended lifetimes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Super-globuling for in vivo extended lifetimes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Super-globuling for in vivo extended lifetimes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1704158